CN114729036B - 抗干细胞因子抗体及其使用方法 - Google Patents

抗干细胞因子抗体及其使用方法 Download PDF

Info

Publication number
CN114729036B
CN114729036B CN202080078693.XA CN202080078693A CN114729036B CN 114729036 B CN114729036 B CN 114729036B CN 202080078693 A CN202080078693 A CN 202080078693A CN 114729036 B CN114729036 B CN 114729036B
Authority
CN
China
Prior art keywords
ser
val
gly
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080078693.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN114729036A (zh
Inventor
M·菲利普斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apsidio Co ltd
Original Assignee
Apsidio Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apsidio Co ltd filed Critical Apsidio Co ltd
Priority to CN202410508865.2A priority Critical patent/CN118561997A/zh
Publication of CN114729036A publication Critical patent/CN114729036A/zh
Application granted granted Critical
Publication of CN114729036B publication Critical patent/CN114729036B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080078693.XA 2019-09-16 2020-09-16 抗干细胞因子抗体及其使用方法 Active CN114729036B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410508865.2A CN118561997A (zh) 2019-09-16 2020-09-16 抗干细胞因子抗体及其使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962900927P 2019-09-16 2019-09-16
US62/900,927 2019-09-16
PCT/US2020/050973 WO2021055408A1 (en) 2019-09-16 2020-09-16 Anti-stem cell factor antibodies and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410508865.2A Division CN118561997A (zh) 2019-09-16 2020-09-16 抗干细胞因子抗体及其使用方法

Publications (2)

Publication Number Publication Date
CN114729036A CN114729036A (zh) 2022-07-08
CN114729036B true CN114729036B (zh) 2024-07-02

Family

ID=74868426

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080078693.XA Active CN114729036B (zh) 2019-09-16 2020-09-16 抗干细胞因子抗体及其使用方法
CN202410508865.2A Pending CN118561997A (zh) 2019-09-16 2020-09-16 抗干细胞因子抗体及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410508865.2A Pending CN118561997A (zh) 2019-09-16 2020-09-16 抗干细胞因子抗体及其使用方法

Country Status (28)

Country Link
US (6) US20220324957A1 (enExample)
EP (3) EP4650367A3 (enExample)
JP (4) JP7717687B2 (enExample)
KR (1) KR20220079561A (enExample)
CN (2) CN114729036B (enExample)
AR (1) AR119979A1 (enExample)
AU (2) AU2020351138A1 (enExample)
BR (1) BR112022004776A2 (enExample)
CA (2) CA3154648A1 (enExample)
CL (1) CL2022000633A1 (enExample)
CO (1) CO2022003661A2 (enExample)
DK (1) DK4031569T3 (enExample)
DO (1) DOP2022000058A (enExample)
EC (1) ECSP22022676A (enExample)
ES (1) ES3053942T3 (enExample)
FI (1) FI4031569T3 (enExample)
IL (1) IL291385A (enExample)
MX (1) MX2022003159A (enExample)
PE (1) PE20230090A1 (enExample)
PH (1) PH12022550647A1 (enExample)
PL (1) PL4031569T3 (enExample)
PT (1) PT4031569T (enExample)
SA (1) SA522431966B1 (enExample)
TW (1) TWI875812B (enExample)
UA (1) UA129546C2 (enExample)
UY (1) UY38883A (enExample)
WO (2) WO2021055408A1 (enExample)
ZA (1) ZA202203272B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217942A1 (en) 2018-05-11 2019-11-14 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
US20220324957A1 (en) 2019-09-16 2022-10-13 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof in renal disease
KR20250167153A (ko) * 2023-03-03 2025-11-28 셀덱스 쎄라퓨틱스, 인크. 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물
WO2026079764A1 (ko) * 2024-10-10 2026-04-16 아주대학교산학협력단 마우스 scf를 중화하는 항체 및 이의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7144731B2 (en) * 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
HUT62011A (en) * 1989-10-16 1993-03-29 Amgen Inc Process for producing factors influencing the functioning of stem cells
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5911988A (en) 1995-04-28 1999-06-15 Bayer Corporation Method for treating asthma using SCF antibody
JP3583214B2 (ja) 1995-12-01 2004-11-04 株式会社ニチレイ ヒトｓｃｆに対するモノクローナル抗体
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US6399857B1 (en) * 1999-09-22 2002-06-04 Paradigm Genetics, Inc. Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species
AR037756A1 (es) * 2001-12-17 2004-12-01 Bayer Corp Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
DK2383295T3 (en) 2003-12-10 2015-06-15 Squibb & Sons Llc Ip-10 antibodies and uses thereof
RU2407752C2 (ru) 2004-04-29 2010-12-27 Оцука Фармасьютикал Ко., Лтд. Антитела к гликопротеину vi и способы продуцирования и использования этих антител
WO2006002064A2 (en) 2004-06-14 2006-01-05 Aerovance, Inc. Antibody inhibiting stem cell factor activity and use for treatment of asthma
US20080248050A1 (en) 2006-06-30 2008-10-09 Uchicago Argonne, Llc Meta-specific vaccine, method for treating patients immunized with meta-specific vaccine
WO2009127046A1 (en) 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
KR20200023495A (ko) 2011-01-10 2020-03-04 더 리젠츠 오브 더 유니버시티 오브 미시간 줄기 세포 인자 억제제
KR101384360B1 (ko) 2012-05-04 2014-04-14 아주대학교산학협력단 Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물
EP4063391A1 (en) 2012-07-25 2022-09-28 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
WO2015006554A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
US10927153B1 (en) 2015-05-20 2021-02-23 University Of South Florida Synthetic plasmodium antigens, compositions, and uses thereof
EP3337827B1 (en) 2015-08-19 2026-07-08 Pfizer Inc. Tissue factor pathway inhibitor antibodies and uses thereof
KR20170022409A (ko) 2015-08-20 2017-03-02 주식회사 와이바이오로직스 Scf 특이적 항체
US11091559B2 (en) * 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
MX2018007818A (es) 2015-12-22 2019-07-01 Abbvie Stemcentrx Llc Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
TWI773693B (zh) 2016-10-05 2022-08-11 新加坡商細胞研究私人有限公司 從臍帶的羊膜分離間質幹細胞的方法、從臍帶的羊膜分離的間質幹細胞群以及用於從臍帶的羊膜分離間質幹細胞的細胞培養基
WO2019066093A1 (ko) 2017-09-26 2019-04-04 주식회사 와이바이오로직스 Scf 특이적 항체
WO2019088658A1 (ko) 2017-10-31 2019-05-09 주식회사 컴워스파마 Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
KR102131898B1 (ko) 2017-10-31 2020-07-08 주식회사 노벨티노빌리티 Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
CN120305401A (zh) 2018-10-19 2025-07-15 总医院公司 用于肝病的治疗的组合物和方法
US20220324957A1 (en) 2019-09-16 2022-10-13 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof in renal disease
JP2024511027A (ja) 2021-03-17 2024-03-12 オプシディオ， エルエルシー 幹細胞因子抗体及びその使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Group 2 innate lymphoid cells（ILC2）are regulated by stem cell factor during chronic asthmatic disease";Wendy Fonseca等;MucosalImmunology;第12卷(第2期);第445-156页、摘要、图1，第446页第1栏、第448页右侧第2-3段 *

Also Published As

Publication number Publication date
US20240076367A1 (en) 2024-03-07
UY38883A (es) 2021-04-30
TW202124434A (zh) 2021-07-01
EP4031569A4 (en) 2023-10-18
JP2022548646A (ja) 2022-11-21
CA3154649A1 (en) 2021-03-25
EP4031176A4 (en) 2023-11-29
DOP2022000058A (es) 2022-08-31
UA129546C2 (uk) 2025-05-28
US20220340655A1 (en) 2022-10-27
DK4031569T3 (da) 2025-11-17
US20230019680A1 (en) 2023-01-19
CN118561997A (zh) 2024-08-30
PL4031569T3 (pl) 2026-02-16
FI4031569T3 (fi) 2025-11-14
MX2022003159A (es) 2022-04-07
US11939373B2 (en) 2024-03-26
ES3053942T3 (en) 2026-01-28
PH12022550647A1 (en) 2023-03-27
US20210079084A1 (en) 2021-03-18
TWI875812B (zh) 2025-03-11
EP4650367A2 (en) 2025-11-19
BR112022004776A2 (pt) 2022-06-21
SA522431966B1 (ar) 2025-05-18
JP7717687B2 (ja) 2025-08-04
WO2021055409A1 (en) 2021-03-25
JP2022547733A (ja) 2022-11-15
EP4031176A1 (en) 2022-07-27
PE20230090A1 (es) 2023-01-16
AU2020351138A1 (en) 2022-03-31
CL2022000633A1 (es) 2022-11-11
AU2020348295A1 (en) 2022-04-07
CO2022003661A2 (es) 2022-04-08
EP4031569A1 (en) 2022-07-27
AR119979A1 (es) 2022-01-26
WO2021055408A1 (en) 2021-03-25
ZA202203272B (en) 2022-12-21
EP4031569B1 (en) 2025-08-20
CN114729036A (zh) 2022-07-08
CA3154648A1 (en) 2021-03-25
US20260193336A1 (en) 2026-07-09
US12410246B2 (en) 2025-09-09
KR20220079561A (ko) 2022-06-13
JP7698635B2 (ja) 2025-06-25
TW202523696A (zh) 2025-06-16
ECSP22022676A (es) 2022-05-31
IL291385A (en) 2022-05-01
JP2025125563A (ja) 2025-08-27
PT4031569T (pt) 2025-11-12
JP2025165991A (ja) 2025-11-05
EP4650367A3 (en) 2026-03-04
US20220324957A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
JP2023078167A (ja) ＳＩＲＰα結合タンパク質及びその使用方法
US12410246B2 (en) Anti-stem cell factor antibodies and methods of blocking the interaction between SCF and c-Kit
JP2023545075A (ja) ＣＤ１ａ抗体およびその使用
CA3212098A1 (en) Stem cell factor antibodies and methods of use thereof
CN111295395A (zh) 抗体和使用方法
RU2844744C1 (ru) Антитела против фактора стволовых клеток и способы их применения
CN118139888A (zh) 抗cldn18.2抗体及其用途
HK40112825A (en) Anti-stem cell factor antibodies and methods of use thereof
HK40078116B (en) Anti-stem cell factor antibodies and methods of use thereof
HK40078116A (en) Anti-stem cell factor antibodies and methods of use thereof
JP2023153754A (ja) ＣＤ１ａ抗体およびその使用
AU2024331270A1 (en) Anti-tslp antibody constructs and uses thereof
CN121399160A (zh) 靶向ccr2的抗体
HK40104632A (en) Stem cell factor antibodies and methods of use thereof
KR20240022546A (ko) 항il-36r 항체 및 그의 사용

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant